NCT05745207View on ClinicalTrials.gov

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

E2086

E2086 tablets.

DRUG

Placebo

E2086 matched placebo tablets.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY